


04-28-03

1651
#7



Attorney's Docket No. 9233.63

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Ekwuribe, et al.
Serial No.: 09/873,797
Filed: June 4, 2001
For:

Group Art Unit: 1651

MIXTURES OF DRUG-OLIGOMER CONJUGATES COMPRISING
POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF
MAKING SAME

PATENT

RECEIVED
APR 28 2003
TECH CENTER 1600/2900

April 24, 2003

Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a form PTO-1449, together with a copy of the identified document(s). This Supplemental Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Accordingly, no fee is required. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 50-0220.

Respectfully submitted,

Shawna Cannon Lemon
Registration No. 53,888



20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EV193585628US
Date of Deposit: April 24, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, Washington, DC 20231.

Vickie Diane Prior

Sheet

1

Of

1

Application Number

Complete if Known

Filing Date

June 4, 2001

First Named Inventor

Ekwuribe

Group Art Unit

1651

Examiner Name

Attorney Docket Number

9233.63

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER NON PATENT LITERATURE DOCUMENTS

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	19 ✓	Francis, G.E., et al., <i>Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting</i> , <i>Journal of Drug Targeting</i> , Vol. 3, pp. 321-40 (1996)	
	20 ✓	Guzman, Angel, et al., <i>Effects of Fatty Ethers and Stearic Acid of the Gastrointestinal Absorption of Insulin</i> , <i>PRHSJ</i> , Vol. 9, No. 2, pp. 155-159 (August 1990)	

Examiner Signature _____

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 Of 2

Compleat if Known

Application Number	09/873,731
Filing Date	June 4, 2001
First Named Inventor	Ekwuribe
Group Art Unit	1711
Examiner Name	Duc Truong
Attorney Docket Number	9233.54

OTHER NON PATENT LITERATURE DOCUMENTS

21 ~	Krishnan, B. Radha, et al., <i>Stability and Physical Characteristics of Orally Active Amphiphilic Human Insulin Analog, Methoxy (Polyethylene Glycol) Hexanoyl Human Recombinant Insulin (HIM2)</i> , <i>Proceed. Int'l. Symp. Control. Rel. Bioact. Mater.</i> , Vol. 27 pp. 1038-39 (2000)
22 ~	Lindsay, D.G., et al., <i>The Acetylation of Insulin</i> , <i>Biochem J.</i> , Vol. 121, pp. 737-745 (1971)
23 ✓	Mesiha, M.S., et al., <i>Hypoglycaemic effect of oral insulin preparations containing Brij 35, 52, 58 or 92 and stearic acid</i> , <i>J. Pharm. Pharmacol.</i> , Vol. 33, pp. 733-34 (1981)
24 ✓	Moghaddam, Amir, <i>Use of polyethylene glycol polymers for bioconjugations and drug development</i> , <i>American Biotechnology Laboratory</i> , pp. 42, 44 (July 2001)
25 ✓	Neubauer, H. Paul, et al., <i>Influence of Polyethylene Glycol Insulin on Lipid Tissues of Experimental Animals, Diabetes</i> , Vol. 32, pp. 953-58 (October 1983)
26 ✓	Shen, Wei-Chiang, et al., (C) Means to Enhance Penetration; (3) Enhancement of polypeptide and protein absorption by macromolecular carriers via endocytosis and transcytosis, <i>Advanced Drug Delivery Reviews</i> , Vol. 8, pp. 93-113 (1992)
27 ✓	Sirokman, Geza, et al., <i>Refolding and proton pumping activity of a polyethylene glycol-bacteriorhodopsin water-soluble conjugate</i> , <i>Protein Science</i> , Vol. 2, pp. 1161-1170 (1993)
28 ✓	Torchilin, Vladimir P., <i>Immunoliposomes and PEGylated Immunoliposomes: Possible Use for Targeted Delivery of Imaging Agents</i> , <i>Immunomethods</i> , Vol. 4, pp. 244-58 (1994)
29 ✓	Wei, Jiang, et al., <i>A Poly(Ethylene Glycol) Water-soluble Conjugate of Porin: Refolding to the Native State</i> , <i>Biochemistry</i> , Vol. 34, pp. 6408-6415 (1995)
30 ✓	Xia, Jiding, et al., <i>Effects of polyoxyethylene chain length distribution on the interfacial properties of polyethylene glycol n-dodecyl ether</i> , <i>Yingyong Huaxue</i> , Vol. 2, No. 4, pp. 59-65 (Abstract Only) (1985)
31	Zalipsky, Samuel, et al., <i>Peptide Attachment to Extremities of Liposomal Surface Grafted PEG Chains: Preparation of the Long-Circulating Form of Laminin Pentapeptide</i> , <i>YIGSR, Bioconjugate Chem.</i> , Vol. 6, pp. 705-8 (1995)

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.